Table 3.

Self-Report Outcomes at Baseline and 2-Month Follow-Up and Regression Results

	Mean(SD)		Coefficient	SE	P value
	STC(N=73)	Control(N=71)
Primary Outcomes
Self-Efficacy
Baseline	7.4(2.6)	7.7(2.4)
Post-Intervention	8.8(2.1)	8.5(1.8)	0.68	0.37	.03
Follow-up	8.2(2.2)	7.8(2.0)	0.84	0.37	.009
Outcome Expectancies
Baseline	7.4(2.5)	7.6(2.3)
Post-Intervention	8.4(2.0)	8.2(2.2)	0.51	0.38	.20
Follow-up	7.8(2.2)	7.8(2.1)	0.22	0.38	.55
Secondary Outcomes
General Clinical Self-Efficacy
Baseline	21.1(3.4)	21.6(3.4)
Follow-up	22.2(3.0)	21.6(3.5)	1.06	0.56	.07
Barriers to Sexual Health Communication
Baseline	30.5(9.9)	29.6(8.9)
Follow-up	27.8(9.9)	29.0(9.0)	−2.19	1.54	.16
Anxiety Symptoms (HADS-A)
Baseline	7.5(4.6)	7.3(4.2)
Follow-up	6.6(4.9)	7.3(4.2)	−0.97	0.46	.04
Depressive Symptoms (HADS-D)
Baseline	5.3(4.0)	4.4(3.4)
Follow-up	4.6(3.7)	4.4(3.5)	−0.06	0.09	.48
QOL (FACT-B)
Baseline	60.8(16.7)	61.9(14.3)
Follow-up	61.8(18.2)	62.6(13.9)	0.69	1.52	.67
Vaginal Lubrication
Baseline	41.6(8.1)	42.8(10.1)
Follow-up	41.6(9.7)	42.2(8.5)	2.04	1.69	.23
Vaginal Discomfort
Baseline	58.0(11.1)	56.1(10.7)
Follow-up	58.4(11.1)	55.8(11.8)	−1.13	1.97	.57
Sexual Satisfaction
Baseline	46.0(9.1)	46.3(8.1)
Follow-up	44.7(7.3)	46.3(8.5)	−0.05	1.61	.98
Sexual Interest
Baseline	36.6(11.9)	35.6(9.9)
Follow-up	37.8(11.2)	35.7(9.7)	0.78	1.47	.60
	n(%)
Sexually Active
Baseline	41/73(56.2)	35/70(50.0)
Follow-up	50/71(70.4)	32/69(46.4)	1.51	0.74	.04

Note: Analyses included all 144 patients except for sexual outcomes; data was available from 86–95 sexually active patients on these outcomes.